TY  - JOUR 
AU  - Álvarez Vázquez, Andrea
AU  - San Segundo, Laura
AU  - Cerveró García, Pilar
AU  - Flores Hernández, Raquel
AU  - Ollauri Ibáñez, Claudia
AU  - Segura Collar, Berta
AU  - Hubert, Christopher G.
AU  - Morrison, Gillian
AU  - Pollard, Steven M.
AU  - Lathia, Justin D.
AU  - Sánchez Gómez, Pilar
AU  - Tabernero Urbieta, María Aránzazu
PY  - 2024
SN  - 1522-8517
UR  - http://hdl.handle.net/10366/167631
AB  - [EN] Background
Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given...
LA  - eng
PB  - Oxford University Press
KW  - Cell-penetrating peptides
KW  - EGFR
KW  - Glioblastoma
KW  - NSCs
KW  - Src
TI  - EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
DO  - 10.1093/neuonc/noae060
T2  - Neuro-Oncology
VL  - 26
M2  - 1230
ER  -